Navigation Links
Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
Date:5/21/2010

BOSTON, May 21 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. today announced presentation of data in a poster titled "Results from a multicenter, open-label Phase 3 study to determine the safety and efficacy of gadobutrol, a macrocyclic 1.0 molar GBCA in patients referred for contrast-enhanced MRI of the central nervous system (CNS)" at the 48th Annual Meeting of the American Society of Neuroradiology (ASNR) in Boston, MA.  The results of this study of this investigational drug met all of its pre-specified primary efficacy objectives.  Gadobutrol is investigational in the United States and is not approved by the U.S. Food and Drug Administration.

This phase 3 study had four primary efficacy objectives.  In results comparing unenhanced CNS MRI versus the combined unenhanced and gadobutrol-enhanced CNS MRI, statistically significant superiority (P<0.0001) of gadobutrol images compared to unenhanced images was shown for all three individual blinded readers as well as the average blinded reader for three of the primary efficacy variables (internal morphology, degree of contrast enhancement and border delineation).  Non-inferiority was the objective for the number of lesions detected in this study and was demonstrated for two of three blinded readers, as well as the average of the blinded readers.(1)

In the study, 14 subjects (4.1%) reported at least one adverse event which the investigators considered related to gadobutrol.  No deaths were reported during the study period, and none of the subjects discontinued from the study due to an AE.  One subject experienced a serious adverse event (SAE), which was not considered by the investigator to be related to the study drug.

"This was a large mu
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Memorial Hermann Health System and The ... a new partnership to provide a new level of specialized ... in the greater Houston area. ... exclusive provider of professional breast radiology services for five of ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... , , ROCHESTER, Minn. , Feb. 5 ... to speed the introduction of new medical treatments developed by ... plaguing the clinical trials process: the lack of a systematic, ... burdens associated with trial start-up administration. , Clinical testing of ...
... SOUTH SAN FRANCISCO, Calif. , Feb. 5 Poniard ... oncology therapies, today announced that Ronald Martell , chief executive officer, ... Investor Conference on Tuesday, February 9, 2010 at 1:00 ... York City . , A live audio webcast of the corporate overview ...
Cached Medicine Technology:Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company 2Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company 3Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company 4Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
(Date:8/22/2014)... The New Jersey Institute for Food, ... University of New Jersey has joined forces with ... educate young people about health and nutrition in a ... both organizations. , The partnership will encompass quarterly custom ... and video communications. ChopChop Magazine features plenty of ...
(Date:8/22/2014)... 2014 (HealthDay News) -- The U.S. Drug Enforcement Administration ... painkillers containing hydrocodone, which has been tied to a ... The new restrictions would cover prescription narcotic drugs such ... in the same regulatory class as painkillers such as ... access to a three-month supply of the drug and ...
(Date:8/22/2014)... low levels of nicotine may reduce addiction without ... new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours of ... of cigarettes with markedly reduced nicotine levels. , ... of which have very similar levels of nicotine ...
(Date:8/22/2014)... The leather seat covers provided ... experts to meet customers’specific product needs. Recently, the company has ... . , The company wants to provide worldwide clients ... the seat cover industry for a long time. According to ... offered at promotional rates. Among all the new products, ...
(Date:8/22/2014)... 2014 AcousticSheep LLC participated in one ... – the first Color Run – otherwise known as the “Happiest ... 2014 and over 10,900 participants from Erie, surrounding areas, and even ... in one of the largest running events put on in Erie, ... the “Happiest 5K on the Planet.” The event took place on ...
Breaking Medicine News(10 mins):Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 2Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 3Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:Custom 1993-1996 Chevrolet Camaro Leather Seat Covers Now for Sale at Lseat.com 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 3
... , , - Ninety-minute Report ... SMILEY and NIGHTLY BUSINESS REPORT - , , ... a major address on healthcare to a joint session of Congress ... and NIGHTLY BUSINESS REPORT are collaborating to provide a timely and ...
... , , LOS ... Dr. Christina Restrepo has achieved diplomate status with the American College ... Restrepo graduated in 2003 from the University of Florida College of ... small animal medicine and surgery at the renowned Animal Medical Center ...
... , , Actuaries Urge President to ... WASHINGTON, Sept. 8 The American Academy of Actuaries ... is expecting there to be an increase in the number of people without ... According to last year,s Census Bureau estimates, nearly 46 million people were ...
... Only Hospital in Northern and Central California to ... REDWOOD CITY, Calif., Sept. 8 Sequoia Hospital announced that ... ablation procedures, making it the highest total volume A-Fib ablation ... Numerous medical journals and world-wide ablation center surveys have documented ...
... when disease will respond to cancer drug , TUESDAY, Sept. ... into whether certain aggressive cancers -- including those that attack ... certain anti-cancer drug. , The key appears to lie in ... 6 online issue of Nature Medicine . , Researchers ...
... diabetes in children, University of Iowa researchers have discovered ... and insulin secretion. The mechanism involves a protein called ... human heart arrhythmias. The findings, which ... Proceedings of the National Academy of Sciences , ...
Cached Medicine News:Health News:PBS Special on Health Care Reform 2Health News:PBS Special on Health Care Reform 3Health News:PBS Special on Health Care Reform 4Health News:Animal Dermatology Clinic Marina del Rey Announces Dr. Christina Restrepo, DVM Achieves Diplomate Status With the American College of Veterinary Dermatology 2Health News:Actuaries: Unemployment May Boost Number of Uninsured 2Health News:Sequoia Hospital Announces High Volume Cardiac Arrhythmia Program 2Health News:Sequoia Hospital Announces High Volume Cardiac Arrhythmia Program 3Health News:Team reveals molecular mechanism underlying a form of diabetes 2
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system....
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
... automated blood gas analysis system that combines ... steps in the analytical process, improve patient ... 1st automatic system consists of the safePICO ... automatic sample handling system. With 1st automatic, ...
Medicine Products: